On Tuesday, America voted to reelect Barack Obama for another four years in office. It was a momentous victory, not only for progressives, but for the health care justice movement.
This post is a guest blog from health care consumer Janet Joy.
Dear Mitt Romney:
A few weeks ago, you told The Columbus Dispatch that even if you’re uninsured “you go to the hospital, you get treated, you get care, and it’s paid for, either by charity, the government or by the hospital. We don’t have people that become ill, who die in their apartment because they don’t have insurance.” I beg to differ.
A quick reference chart that outlines required and optional changes to Medicaid that make the eligibility process for applicants more streamlined and consumer-friendly.
Find out how to get involved in developing Medicaid health homes, one of the ways states can get funding from the Affordable Care Act to provide coordinated, patient-centered care.
The Kaiser Family Foundation and the Urban Institute just published a study re-examining the impact that the 2012 Republican budget plan would have on state Medicaid programs. This is the budget plan developed and championed by Vice Presidential candidate Paul Ryan. The plan—voted for by all House Republicans—calls for ending Medicare as we know it, making deep cuts in federal support for Medicaid, and turning Medicaid into a block grant program.
This blog was originally posted at Huffingtonpost.com
Opponents of Obamacare (the Patient Protection and Affordable Care Act for those who prefer the formal title) often assert with great confidence that it will take away job-based health insurance from American workers. Yet analyses by the Congressional Budget Office, the Rand Corporation, and the Urban Institute do not support this conclusion at all. In fact, the evidence shows just the opposite: Obamacare will increase job-based coverage.
Supporters of the Romney-Ryan plan for Medicare like to say that the major changes that are part of their proposal don’t take effect for 10 years and therefore people who currently have Medicare won’t be affected. Well, there are at least five reasons why the changes that take effect right away matter a lot to people with Medicare right now.
Is newer always better? Not in the case of a pricey new cancer drug, according to clinical trial data and experts around the nation. The drug, Zaltrap, is getting lots of media attention not because it is novel for a new drug to be twice as expensive as its competitor and no more effective (the FDA doesn't require new medicines to be either more effective or less costly than existing drugs), but because Memorial Sloan-Kettering Cancer Center—one of the nation's premier cancer treatment centers—has decided that it won't offer Zaltrap to its patients.